Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.55 |
| ▸ | NPY1R | P25929 | 9/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.55 |
| ▸ | NPY2R | P49146 | 5/20 | 0.55 |
| ▸ | FNTA | P49354 | 3/20 | 0.51 |
| ▸ | FNTB | P49356 | 3/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL230814 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL8587360 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL2341079 | 0.99 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL2341088 | 0.99 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL1940080 | 0.98 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL1727152 | 0.98 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL1727150 | 0.98 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL30866932 | 0.93 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL29619346 | 0.91 | FNTA (0.60) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL29352845 | 0.91 | FNTA (0.58) | NPY4RNPY1RNPY5RNPY2RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8569314-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2009120684-A1 | ANTIBODY FORMULATION | MEDIMMUNE, LLC (US) | 2009-10-01 | — | — | WO | disclosed |
| US-6863790-B1 | Sheathless interface for capillary electrophoresis/electrospray ionization-mass spectrometry using an in-capillary electrode | BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM (US) | 2005-03-08 | — | — | US | disclosed |
| WO-1998035226-A1 | A NOVEL SHEATHLESS INTERFACE FOR CAPILLARY ELECTROPHORESIS/ELECTROSPRAY IONIZATION-MASS SPECTROMETRY USING AN IN-CAPILLARY ELECTRODE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038988-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | NPY4R 4303/4885NPY1R 4756/4885NPY5R 4267/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | NPY4R 4303/4885NPY1R 4756/4885NPY5R 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.